Phase 2
Completed N=167
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer
Source: ClinicalTrials.gov NCT01769391 ↗Enrolled (actual)
167
Serious AEs
39.8%
Results posted
May 2016
Primary outcomePrimary: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR]) — 48.9; 40.0 percentage of participants
Summary
The main purpose of this study is to evaluate if necitumumab added to standard chemotherapy of paclitaxel and carboplatin is more effective to treat cancer than the standard chemotherapy of paclitaxel and carboplatin alone.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR]) |
48.9; 40.0 | — |
| SECONDARY Overall Survival (OS) |
13.2; 11.2 | — |
| SECONDARY Pharmacokinetics (PK): Maximum Concentration (Cmax) of Necitumumab |
262.418; 296.843; 303.475 | — |
| SECONDARY Percentage of Participants With Anti Necitumumab Antibodies |
2.8 | — |
| SECONDARY Progression-Free Survival |
5.4; 5.6 | — |
| SECONDARY Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR]) |
87.2; 84.0 | — |
| SECONDARY Percent Change in Tumor Size (CTS) |
-44.3; -38.65 | — |
| SECONDARY Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab |
59.269; 47.874; 78.142; 80.392; 89.137; 87.043 | — |
Eligibility Criteria
Inclusion Criteria
- Histologically or cytologically confirmed squamous NSCLC
- Stage IV disease at time of study entry based on American Joint Committee on Cancer (AJCC) 7th edition
- Measurable disease at time of study entry as defined by Response Evaluation Criteria in Solid Tumors, (RECIST) Version 1.1
- Archived or recent tumor tissue (minimum of 5 unstained tissue slides or a paraffin-embedded tissue block) available for analysis of epidermal growth factor receptor (EGFR) protein expression by immunohistochemistry (IHC) and other biomarker assessments
Exclusion Criteria
- Nonsquamous NSCLC
- Prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the EGFR, vascular endothelial growth factor (VEGF), or VEGF receptor
- Previous chemotherapy for NSCLC
- Major surgery or received any investigational therapy in the 4 weeks prior to randomization
- Chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions, which is allowed)
- Brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants (Participants who have undergone previous radiotherapy for brain metastases, who are now nonsymptomatic and no longer require treatment with steroids or anticonvulsants, are eligible)
Data sourced from ClinicalTrials.gov (NCT01769391). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.